echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > [Lymphoma Micro-Class 2021ASH Express] Assessment of Quality of Life of Chinese CLL Patients

    [Lymphoma Micro-Class 2021ASH Express] Assessment of Quality of Life of Chinese CLL Patients

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fellow fellows, hello everyone, and welcome to the lymphoma micro-class
    .

    I am Dr.
    Peng Hongling from the Department of Hematology, Xiangya Second Hospital of Central South University
    .

    Today I will mainly introduce to you a real-world study on the quality of life assessment of Chinese patients with chronic lymphocytic leukemia (CLL) conducted by our hospital and the Institute of Psychology, Central South University
    .

    This research was accepted by this year's ASH conference in abstract form
    .

    We know that the natural history of different CLL patients is different.
    For patients with inactive disease, the survival period can reach more than 10 years; for some patients, the disease progresses rapidly, and the median survival period is only 3-4 years
    .

    Moreover, none of the existing treatment methods can completely cure the disease, which will undoubtedly bring certain life, economic and psychological burdens to patients and their families
    .

    Compared with patients with solid tumors, there are currently fewer studies evaluating the quality of life of CLL patients.
    We hope to explore the psychological status and quality of life of CLL patients in China through this study
    .

    In the study, we mainly used three scales
    .

    The first two are the quality of life questionnaires of the European Organization for the Treatment of Cancer (EORTC): QLQ-C30 and QLQ-CLL17, which are mainly used to measure the patient’s disease-related symptoms, overall physical condition, concerns about physical function and psychological status; The last one is the DASS-21 scale, which is used to measure the patient’s mood, including the patient’s depression, anxiety, and stress
    .

    A total of 50 CLL patients were enrolled, of which 34 patients were men
    .

    The median age is 57 years
    .

    Among them, 66% of patients were unaware of their disease classification, and 36% of patients were unaware of their disease treatment
    .

    According to the analysis of the EORTC QLQ-C30 scale, CLL patients have impairments in various dimensions, including: 80% of patients with impaired physical function, 32% of patients with impaired role function, and 68% of patients with impaired emotional function.
    Patients with impaired cognitive function accounted for 66%, and patients with social function loss accounted for 64%
    .

    In addition, the study also found that the proportion of patients undergoing treatment with impaired cognitive function was significantly higher than that of patients in watchful waiting, the proportions were 90% and 65%, respectively, p=0.
    03
    .

    Among female patients, the percentage of cognitive impairment was also significantly higher than that of male patients, 93.
    8% and 52.
    9%, respectively, p=0.
    004
    .

    In the QLQ-CLL17 scale, we found that 94% of patients showed a burden of symptoms, 86% of patients had varying degrees of physical impairment, and 98% of patients showed concerns about the disease
    .

    The proportion of this kind of worry and fear is significantly higher in patients under the age of 60
    .

    This change in the patient's psychological status is also consistent with the results of the DASS-21 scale
    .

    According to the results of DASS-21, 86% of patients experienced depression of varying degrees, of which 52% of patients were moderately depressed, and 32% of patients were severe or extremely depressed
    .

    84% of patients have varying degrees of anxiety, of which 64% are severe or above
    .

    Another 64% of patients felt a lot of pressure, mostly moderate and severe
    .

    And these psychological problems are not affected by gender, age, family income and treatment
    .

    In addition, we received sequential questionnaires from 5 patients.
    We found that compared with the initial assessment, the patient’s emotional impairment was deeper, but the patient’s physical activity, cognitive function, and social function were in the two assessments.
    There is no significant change
    .

    Through this study, we found that CLL patients usually have quality of life and psychological problems, especially in patients undergoing treatment, their physical functions are more deeply affected
    .

    The cognitive function of male patients is relatively better, and younger patients have more serious health concerns than older patients
    .

    These research results also remind us clinicians how to pay attention to the patient's psychological changes while managing the disease progression of CLL patients.
    In addition, we also look forward to follow-up studies that will allow us to see whether the quality of life and psychological burden of patients can be obtained through treatment.
    Improve
    .

    This is the end of this lymphoma micro-class, thank you for listening and watching, thank you! Professor Hongling Peng, Doctor of Medicine, Doctoral Supervisor, Chief Physician, and Professor, Director of the Department of Hematology, Xiangya Second Hospital of Central South University, Director of the Molecular Hematology Research Center of Central South University Member of the Tumor Professional Committee Member of the Chinese MDS and MPN Working Group Member of the Hematology Branch of the Hunan Geriatrics Association Executive Vice Chairman and Secretary-General of the Chronic Lymphocytic Leukemia Group of Hunan Province Vice Chairman of the Hunan Provincial Society of Hematology, Chinese Medical Association Member of the Lymphoma Professional Committee of the Association, Executive Director of the Blood Health Branch of the Hunan Health Service Industry Association, Dana-Farber Cancer Institute, Harvard University, visiting scholar/postdoctoral fellow, published more than 20 SCI papers, presided over three National Natural Science Foundation projects, and three provincial-level projects.
    Two Central South University Medical New Technology Awards⦅Chinese Journal of Hematology⦆The tenth edition of the editorial board has long been engaged in lymphatic tumor intervention strategies and hereditary hematological research.
    Statement: Xi’an Janssen does not recommend the use of over-instructions CRC Number: MED-ONC- CN-2620 approved date: 2021/12/08 References: Heng Li, Qiaoping Lian, Peilong Wang, Yin Le, Yue Sheng, Daxing Wu, Hongling Peng; Assessment of Quality of Life in Chinese Patients with Chronic Lymphocytic Leukemia.
    Blood 2021 ; 138 (Supplement 1): 5028.
    doi: https://doi.
    org/10.
    1182/blood-2021-149128.
    Stamp "read the original text" and we will make progress together
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.